Christopher Teas

Christopher is the Co-Founder and the current CEO of CAD Therapeutics a clinical stage biotech treating PTSD and Addiction. He has successfully implemented AI Algorithms for remote patient monitoring to collect and analyze patient data. As owner of a drug manufacturing enterprise Christopher integrated AI algorithms in controlling drug quality by analyzing manufacturing data, monitoring equipment, and analyzing energy consumption. In finance, he uses AI algorithms in security selection, portfolio design and risk management.

He is the Managing Partner and Co-Founder of Park South Capital, a single-family office focused on direct majority control investments across multiple sectors including: Fintech, TMT, Biotech, Asset Management, Insurance and Banking. Christopher is an experienced, results driven executive who has worked in capital markets and private equity for over 35 years.

Christopher has significant experience and excellent track record in building businesses, managing large teams, and structuring complex transactions. Christopher earned his BA from Lewis & Clark College and studied at Institut Catholique, Paris France.